Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Expanding access to lung cancer clinical trials by reducing the use of restrictive exclusion criteria: Perspectives of a multi-stakeholder working group

(2020) Patrick M. Forde et al.   Clinical Lung Cancer

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations

(2020) Enriqueta Felip et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

(2020) Gary Middleton et al.   Lancet Respiratory Medicine

Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

(2019) Alessio Cortellini et al.   ONCOLOGIST

Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence

(2019) Antonio Passaro et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153)

(2019) David R. Spigel et al.   Journal of Thoracic Oncology

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population

(2019) Lucio Crinò et al.   ONCOLOGIST

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

(2019) Natasha B Leighl et al.   Lancet Respiratory Medicine

Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies

(2019) KOHEI FUJITA et al.   ANTICANCER RESEARCH

Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting

(2019) Jason C Simeone et al.   Future Oncology

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

(2019) Kaname Nosaki et al.   LUNG CANCER

LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study

(2019) R S Herbst et al.   ANNALS OF ONCOLOGY

Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations?

(2019) R. Califano et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

(2019) Hisao Imai et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

(2018) François-Xavier Danlos et al.   EUROPEAN JOURNAL OF CANCER

Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis

(2018) Sandhya Manohar et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

(2018) A. Bernard-Tessier et al.   EUROPEAN JOURNAL OF CANCER

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer

(2018) Maiko Niki et al.   Oncotarget

P1.06-020 Prevalence of Autoimmune Disease in US Veterans With Non-Small Cell Lung Cancer (NSCLC)

(2017) Manali Patel et al.   Journal of Thoracic Oncology

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153

(2017) David Spigel et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

(2017) Peng-Fei Wang et al.   Frontiers in Pharmacology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research

(2008) Rogerio C. Lilenbaum et al.   Journal of Thoracic Oncology